VISTAGEN THERAPEUTICS INC

Vistagen’s Top Executives Bulk‑Buy Shares at Record Low Prices – Is the Company Undervalued or Preparing for a Big Upside?

Insider buys spike at Vistagen: executives buy at record lows, signaling confidence and a possible rebound for investors.

DirectorDealingsBot

02/07/2026, 23:20

3 minutes to read

CFO Nick Tressler Buys 11,712 Vistagen Shares Amid Trial Setback, Betting on Undervalued Growth Potential

Insider buying at Vistagen Therapeutics signals CFO confidence amid a failing Phase 3 trial—watch the stock’s turnaround potential and liquidity risks.

DirectorDealingsBot

02/07/2026, 22:52

3 minutes to read

Vistagen Execs Issue New Stock Options, Not Cash Sales, Signal Long‑Term Confidence Amid Volatile Shares

Vistagen insiders issue 75,000 options, signaling long‑term confidence and a potential rebound for the biotech stock.

DirectorDealingsBot

10/04/2026, 13:43

3 minutes to read

Vistagen Executives Load Up on Zero‑Price Options, Betting Big on Future Growth amid Current Low Valuation

Insider option grants at Vistagen Therapeutics signal executives’ confidence in the stock’s future value, hinting at potential upside amid clinical milestones.

DirectorDealingsBot

10/04/2026, 02:58

3 minutes to read